Lindholm T S, Eriksson S
Scand J Rheumatol. 1982;11(1):55-7. doi: 10.3109/03009748209098116.
A series of osteoporotic patients treated for 25 months (average) with 1 alpha-hydroxyvitamin D3 (1 alpha-OHD3) supplemented with calcium were examined in respect of calcium metabolism and bone mineral changes before, during, and 12 months after cessation of treatment. The bone mineral content, which increased during treatment, showed a decreasing post-treatment tendency. The decrease was more obvious in patients with senile osteoporosis. The levels of serum calcium and phosphate stayed within normal levels. The urinary calcium excretion rate, which also rose during treatment, returned to pre-treatment values after discontinuing treatment. Excretion of urinary phosphate, however, showed a tendency towards further decrease. Serum PTH stayed within normal levels, while serum alkaline phosphatase, which was depressed during treatment, rose again after treatment. The investigation speaks in favour of a continuous administration of 1 alpha-OHD3 and calcium which is generally noted to increase bone mineral during long-term treatment.
对一系列接受1α-羟基维生素D3(1α-OHD3)加钙治疗25个月(平均)的骨质疏松症患者,在治疗前、治疗期间及停止治疗后12个月,就钙代谢和骨矿物质变化进行了检查。治疗期间增加的骨矿物质含量在治疗后呈下降趋势。这种下降在老年性骨质疏松症患者中更为明显。血清钙和磷水平保持在正常范围内。治疗期间也升高的尿钙排泄率在停药后恢复到治疗前的值。然而,尿磷排泄呈进一步下降趋势。血清甲状旁腺激素保持在正常水平,而治疗期间降低的血清碱性磷酸酶在治疗后再次升高。该研究支持持续给予1α-OHD3和钙,一般认为在长期治疗期间这会增加骨矿物质。